Eyerising International myopia management device has been listed in the Australian Therapeutic Goods Administration.
This technology is indicated for the treatment of myopia at home with low-level red light therapy.
The company said the device is already widely used overseas. It said that at the current rates of progression, it is anticipated that one in two people globally will be myopic by 2050, with nearly 10 per cent at risk of high myopia.
The company said it has finalised distribution licenses, and the first sales have occurred in Japan, New Zealand and Turkey, and that it is targeting a minimum rollout in ten countries by the end of 2023.